The Beauty Health Company (SKIN) Financial Ratios
7 years of historical data (2019–2025) · Consumer Defensive · Household & Personal Products
EV/EBITDA
7290.48
↓-22% vs avg
5yr avg: 9298.88
P/FCF
↓
3.13
↓-88% vs avg
5yr avg: 25.47
30Y Low5.1·High47.1
P/B Ratio
↓
2.00
↓-67% vs avg
5yr avg: 6.12
30Y Low3.1·High8.2
ROE
↑
-16.8%
↓+80% vs avg
5yr avg: -83.4%
30Y Low-278%·High19%
Debt/EBITDA
10519.44
+0% vs avg
5yr avg: 10519.44
30Y Low7.0·High7.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SKIN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
The Beauty Health Company currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 3.1x P/FCF, 88% below the 5-year average of 25.5x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $116M | $189M | $227M | $410M | $1.4B | $2.5B | $388M | — |
| Enterprise Value | $262M | $335M | $425M | $639M | $1.5B | $2.3B | $595M | — |
| P/E Ratio → | -5.62 | — | — | — | — | — | — | — |
| P/S Ratio | 0.39 | 0.63 | 0.68 | 1.03 | 3.69 | 9.49 | 3.26 | — |
| P/B Ratio | 2.00 | 3.09 | 4.37 | 6.90 | 8.09 | 8.16 | — | — |
| P/FCF | 3.13 | 5.08 | 24.26 | 47.07 | — | — | — | — |
| P/OCF | 3.11 | 5.03 | 14.04 | 18.83 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SKIN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
The Beauty Health Company's enterprise value stands at 7290.5x EBITDA, 22% below its 5-year average of 9298.9x. The Consumer Defensive sector median is 11.5x, placing the stock at a 63323% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.11 | 1.27 | 1.61 | 4.20 | 8.89 | 5.00 | — |
| EV / EBITDA | 7290.48 | 9298.88 | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | 26.14 | — | — | — |
| EV / FCF | — | 9.00 | 45.47 | 73.42 | — | — | — | — |
SKIN Profitability
Margins and return-on-capital ratios measuring operating efficiency
The Beauty Health Company earns an operating margin of -6.9%, below the Consumer Defensive sector average of 1.5%. Operating margins have expanded from -32.9% to -6.9% over the past 3 years, signaling improving operational efficiency. A negative ROE of -16.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.3% | 65.3% | 54.5% | 39.0% | 68.0% | 68.6% | 56.4% | 63.9% |
| Operating Margin | -6.9% | -6.9% | -20.3% | -32.9% | -7.1% | -15.4% | -14.4% | 8.1% |
| Net Profit Margin | -3.2% | -3.2% | -8.7% | -25.2% | 12.1% | -145.6% | -24.5% | -1.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -16.8% | -16.8% | -52.3% | -88.4% | 18.8% | -278.2% | — | — |
| ROA | -1.6% | -1.6% | -3.6% | -10.4% | 4.0% | -52.5% | -13.0% | -0.7% |
| ROIC | -6.8% | -6.8% | -18.9% | -30.7% | -7.8% | -18.5% | -7.2% | 5.6% |
| ROCE | -4.5% | -4.5% | -9.5% | -15.0% | -2.5% | -6.0% | -9.0% | 7.1% |
SKIN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The Beauty Health Company carries a Debt/EBITDA ratio of 10519.4x, which is highly leveraged (312452% above the sector average of 3.4x). Net debt stands at $146M ($379M total debt minus $233M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 6.20 | 6.20 | 10.97 | 12.67 | 4.50 | 2.47 | — | — |
| Debt / EBITDA | 10519.44 | 10519.44 | — | — | — | — | — | 6.99 |
| Net Debt / Equity | — | 2.39 | 3.82 | 3.86 | 1.10 | -0.51 | — | — |
| Net Debt / EBITDA | 4055.56 | 4055.56 | — | — | — | — | — | 6.72 |
| Debt / FCF | — | 3.93 | 21.21 | 26.35 | — | — | — | — |
| Interest Coverage | -1.08 | -1.08 | -1.84 | -6.46 | 4.39 | -31.32 | -0.81 | 0.83 |
SKIN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.66x means The Beauty Health Company can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 6.07x to 1.66x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.66 | 1.66 | 7.00 | 6.07 | 10.92 | 13.09 | 1.91 | 1.43 |
| Quick Ratio | 1.40 | 1.40 | 5.99 | 5.28 | 9.39 | 12.63 | 1.16 | 0.92 |
| Cash Ratio | 1.25 | 1.25 | 5.43 | 4.55 | 7.92 | 11.80 | 0.31 | 0.19 |
| Asset Turnover | — | 0.60 | 0.49 | 0.43 | 0.36 | 0.21 | 0.53 | 0.74 |
| Inventory Turnover | 2.17 | 2.17 | 2.20 | 2.66 | 1.07 | 2.31 | 2.24 | 3.09 |
| Days Sales Outstanding | — | 28.44 | 31.08 | 50.47 | 77.59 | 72.17 | 71.06 | 51.96 |
SKIN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
The Beauty Health Company does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | 31.9% | 19.7% | 4.1% | 2.1% | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.9% | 7.9% | 11.8% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.9% | 7.9% | 11.8% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $136M | $142M | $132M | $149M | $102M | $34M | $32M |
Peer Comparison
Compare SKIN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SKINYou | $116M | -5.6 | 7290.5 | 3.1 | 65.3% | -6.9% | -16.8% | -6.8% | 10519.4 |
 ELF | $3B | 30.9 | 17.2 | 28.7 | 71.2% | 12.0% | 16.0% | 13.5% | 1.5 |
 IPAR | $3B | 17.5 | 11.1 | 15.4 | 63.6% | 18.2% | 16.5% | 18.6% | 0.8 |
 COTY | $2B | -5.8 | 9.4 | 8.1 | 64.8% | 4.1% | -9.0% | 2.3% | 6.4 |
 NUS | $353M | 2.3 | 6.0 | 7.7 | 69.4% | 4.4% | 22.0% | 5.5% | 4.3 |
 USNA | $355M | 33.2 | 2.3 | 41.7 | 78.3% | 5.5% | 1.8% | 8.6% | 0.2 |
 ESTA | $2B | -41.3 | — | — | 69.3% | -18.5% | -133.3% | -42.1% | — |
 INMD | $912M | 10.1 | 7.2 | 10.8 | 78.5% | 23.0% | 13.5% | 13.5% | 0.2 |
 SSKN | $6M | -0.6 | — | — | 56.9% | -27.6% | -114.2% | -38.9% | — |
 ULTA | $24B | 20.8 | 5.4 | 22.8 | 39.1% | 39.1% | 43.6% | 87.9% | 0.5 |
 SBH | $1B | 7.3 | 6.4 | 7.8 | 51.6% | 8.9% | 27.5% | 11.4% | 3.7 |
| Consumer Defensive Median | — | 19.1 | 11.5 | 14.9 | 40.2% | 1.5% | 7.7% | 5.5% | 3.4 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See SKIN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SKIN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SKIN vs ELF
Side-by-side business, growth, and profitability comparison vs e.l.f. Beauty, Inc..
Start ComparisonSKIN — Frequently Asked Questions
Quick answers to the most common questions about buying SKIN stock.
What is The Beauty Health Company's P/E ratio?
The Beauty Health Company's current P/E ratio is -5.6x. This places it at the 50th percentile of its historical range.
What is The Beauty Health Company's EV/EBITDA?
The Beauty Health Company's current EV/EBITDA is 7290.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
What is The Beauty Health Company's ROE?
The Beauty Health Company's return on equity (ROE) is -16.8%. The historical average is -83.4%.
Is SKIN stock overvalued?
Based on historical data, The Beauty Health Company is trading at a P/E of -5.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are The Beauty Health Company's profit margins?
The Beauty Health Company has 65.3% gross margin and -6.9% operating margin.
How much debt does The Beauty Health Company have?
The Beauty Health Company's Debt/EBITDA ratio is 10519.4x, indicating high leverage. A ratio above 4x may signal elevated financial risk.